HOUSE-BILL 1051: H.R.1051 - To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.
AI-Powered Summary
HOUSE-BILL 1051 aims to enhance the availability of generic drugs by allowing subsequent applicants to gain approval for abbreviated new drug applications if the first applicant fails to market the drug within a specified timeframe. This legislation addresses major themes such as competition in the pharmaceutical market and access to affordable medication, potentially lowering drug prices for consumers. Key provisions include the introduction of a 180-day exclusivity period for first applicants, conditions for subsequent applicant approval, and special forfeiture rules to expedite market entry for generics. The implementation of these provisions is expected to improve public health outcomes by ensuring timely access to medications. However, potential constitutional concerns may arise regarding the balance between pharmaceutical innovation and public access, as well as due process implications related to the approval criteria. Overall, the bill seeks to promote a more competitive drug market while safeguarding consumer rights.
Demographic Impact Analysis
Summary
Overall Constitutional Implications
The bill has significant implications for individual rights, particularly in enhancing access to affordable medications. This aligns with broader constitutional principles regarding health and welfare, although it raises concerns about equitable access across different demographic groups.
Key Individual Rights
- Right to Health Care Access
- Equal Protection under the Law
Constitutional Provisions
- 14th Amendment - Equal Protection Clause
- Commerce Clause (Article I, Section 8)
Potential Constitutional Challenges
While the bill aims to improve access to medications, it may face challenges if it disproportionately benefits certain demographic groups over others, potentially violating the Equal Protection Clause. Additionally, concerns about the balance between encouraging pharmaceutical innovation and ensuring access to affordable drugs could arise.
Summary
HOUSE-BILL 1051 seeks to facilitate the approval of generic drugs, potentially increasing access to affordable medications for individuals across various demographic categories. While it supports the right to health care access and aligns with equal protection principles, careful implementation is necessary to avoid exacerbating existing disparities among vulnerable populations.
Constitutional Analysis
This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.
Analysis generated using AI-powered review of constitutional principles and legal precedents.
Take Action
Text 50409
💡 How to use:
These links will start a conversation with ResistBot. When prompted, mention H.R. 1051 to reference this bill.
Contact Your Representatives
Write to YOUR elected officials about this bill
Rate This Bill
Sign in to save a private rating for this bill and track your civic engagement over time.
Sign In FreeTimeline
February 6, 2025
Bill Introduced
Current
Referred to Committee
June 12, 2026
Last Updated
Ask the Constitutional AI About This Bill
Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.
Sign In Free to Chat